-

11:32:56 AM

KMDA Stock News

KMDA - Kamada Ltd

05/24/23 7:10 AM

Nasdaq : KMDA

earnings

Kamada Reports Strong First Quarter 2023 Financial Results; Reiterates Revenue and Profitability Guidance

Total Revenues for First Quarter of 2023 were $30.7 Million, Up 9% Year-over-Year First Quarter 2023 EBITDA of $3.8 Million, Increase of 16% Year-over-Year Solid First Quarter Results and Expected Continued Momentum Supported by Multiple Growth Drivers Anticipated to Drive Full-Year 2023 EBITDA

RHEA-AI

neutral

05/24/23 7:05 AM

Nasdaq : KMDA

management

Kamada Announces Chief Financial Officer Chaime Orlev to Remain in Role and Appointment of Nir Livneh as Vice President, General Counsel and Corporate Secretary

Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA) (“Kamada” or the “Company”), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the

RHEA-AI

neutral

05/24/23 7:00 AM

Nasdaq : KMDA

Kamada Announces $60 Million Private Placement with FIMI Opportunity Funds

Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA) (“Kamada” or the “Company”), a commercial stage global biopharmaceutical company

RHEA-AI

neutral

05/17/23 7:00 AM

Nasdaq : KMDA

earnings

Kamada to Announce First Quarter 2023 Financial Results and Host Conference Call on May 24, 2023

Kamada Ltd. (NASDAQ & TASE: KMDA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today

RHEA-AI

neutral

05/16/23 7:00 AM

Nasdaq : KMDA

Kamada Announces Receipt of Marketing Authorization for Glassia® for Treatment of Alpha-1 Antitrypsin Deficiency in Switzerland

Switzerland is the first European country to approve Glassia ®, which received U.S. FDA approval in 2010 Glassia will be commercialized by IDEOGEN AG in Switzerland and the therapy is expected to be available to patients and providers during the second half of 2023 The current Alpha-1 Antitrypsin

RHEA-AI

neutral

05/03/23 7:00 AM

Nasdaq : KMDA

fda approval

Kamada Announces U.S. FDA Approval of its Application to Manufacture CYTOGAM® at the Company’s Facility in Israel

Sales of CYTOGAM® Highest Among Four IgG Products Acquired in November 2021 with Approximately $23 Million in Revenues in 2022 , and Gross Margins Over 50% Approval to Manufacture CYTOGAM at Kamada’s Facility to Positively Impact Plant Utilization and Efficiency REHOVOT, Israel and HOBOKEN, N.J.,

RHEA-AI

very positive

03/15/23 7:10 AM

Nasdaq : KMDA

Kamada Issues 2023 CEO Letter to Shareholders

Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field,

RHEA-AI

very positive

03/15/23 7:00 AM

Nasdaq : KMDA

earnings

Kamada Reports Strong Fiscal Year and Fourth Quarter 2022 Financial Results, and Provides 2023 Guidance Representing Significant Profitability Growth

Total Revenues for Fiscal Year 2022 of $129.3 Million Represent ed Growth of 25% Compared to Fiscal Year 2021 ; Fourth Quarter 2022 Revenues of $45. 4 Million Represent ed a 44% Increase Year - over - Year Fiscal Year 2022 EBITDA of $1 7.8 million, Represent ed Margins of 14%, and a 3x Increase

RHEA-AI

positive

03/09/23 8:00 AM

Nasdaq : KMDA

earnings

Kamada to Announce Fourth Quarter and Full Year 2022 Financial Results and Host Conference Call on March 15, 2023

Kamada Ltd. (NASDAQ & TASE: KMDA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today

RHEA-AI

neutral

01/04/23 7:00 AM

Nasdaq : KMDA

Kamada Announces Submission of Application to the U.S. FDA to Manufacture CYTOGAM® at the Company’s Facility in Israel

FDA Approval Currently Expected by Mid-2023 Sales of CYTOGAM® Highest Among Four IgG Products Acquired in November 2021, with Gross Margins Over 50% Ability to Manufacture CYTOGAM at Kamada’s Facility to Positively Impact Plant Utilization and Efficiency REHOVOT, Israel and HOBOKEN, N.J. , Jan.

RHEA-AI

very positive

KMDA Data

IndustryPharmaceutical Preparation Manufacturing
Websitekamada.com
Security nameKamada Ltd
Issue typecs
SectorManufacturing
Sic code2834
Employees380
Tags
- Health Technology
- Biotechnology

About Kamada Ltd

kamada ltd. is focused on plasma-derived protein therapeutics for orphan indications, and has a commercial product portfolio and a robust late-stage product pipeline. the company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce alpha-1 antitrypsin (aat) in a highly-purified, liquid form, as well as other plasma-derived proteins. aat is a protein derived from human plasma with known and newly-discovered therapeutic roles given its immunomodulatory, anti-inflammatory, tissue-protective and antimicrobial properties. the company’s flagship product is glassia®, the first and only liquid, ready-to-use, intravenous plasma-derived aat product approved by the u.s. food and drug administration. kamada markets glassia in the u.s. through a strategic partnership with baxter international. in addition to glassia, kamada has a product line of nine other pharmaceutical products that are marketed through distributor